NeuroOne Medical Technologies: Key Insights on 2025 Equity Incentive Plan Filing

Here are the key insights and information extracted from the provided financial report section:

1. Document Type and Purpose:

• This is a Current Report on Form 8-K/A, which signifies it is an amendment to a previously filed report (Original 8-K) by NeuroOne Medical Technologies Corporation.
• The amendment is specifically to include Item 5.02 regarding the approval of the 2025 Equity Incentive Plan by the stockholders.

2. Company Information:

• Name: NeuroOne Medical Technologies Corporation
• CIK: 0001500198
• SEC File Number: 001-40439
• IRS Employer Identification Number: 27-0863354
• Address: 7599 Anagram Dr., Eden Prairie, MN 55344
• Contact Number: 952-426-1383

3. Stock Information:

• The company’s common stock has a par value of $0.001 per share and is traded on NASDAQ under the ticker symbol "NMTC".

4. Date of Filing:

• The filing date for both the original and amended reports is February 14, 2025.

5. Key Actions:

• The amendment includes details about the 2025 Equity Incentive Plan, which was approved at the annual meeting of stockholders held on the same date (February 14, 2025).
• The amendment intends to restate the Original 8-K in its entirety and includes the plan and related agreements as exhibits.

6. Importance of the 2025 Equity Incentive Plan:

• This plan is significant as it likely relates to employee compensation and incentives, which can affect the company’s ability to attract and retain talent.

7. Exhibits and Attachments:

• The filing includes the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan and forms of Restricted Stock Unit Agreement and Option Grant Agreement.

Overall, this filing is important for stakeholders interested in the company’s governance practices, compensation strategies, and overall financial health as it relates to employee incentives.